Aditum Bio
Jenelle Lin is an accomplished clinical operations professional with extensive experience in leading pivotal clinical studies across various therapeutic areas. Currently serving as the Associate Director of Clinical Operations at Aditum Bio, Jenelle oversees clinical operations for Motric Bio, focusing on therapies for neurological injuries and diseases. As an advisor to FAST California, Jenelle supports innovative life science technology companies in refining their business models and developing strategic plans. Previously, in roles at Vir Biotechnology, BridgeBio, and FibroGen, Jenelle managed significant global clinical trials, including the FDA and EMA approved Attruby™ for rare disease. Jenelle holds a Master of Science in Epidemiology and Public Health from the University of Miami and completed an Executive Education Program at Stanford University.
This person is not in any teams
Aditum Bio
Aditum Bio is an investment fund that specializes in acquiring and developing pharmaceutical assets. It gives patients access to medicines that may not otherwise be developed. Aditum Bio was founded on 2019 and is headquartered in San Francisco, California.